All In Biotech

Drug Trial Radar · NCT06914908

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

71

Actual

Start

May 12, 2025

Primary completion

Feb 22, 2029

Study completion Feb 22, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Apr 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 148 weeks per participant, including 144 weeks of treatment period and 4 weeks of follow-up.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • LunsekimigDrug

    * Pharmaceutical form: solution for injection * Route of administration: subcutaneous

  • Mometasone furoate nasal spray (MFNS)Drug

    * Pharmaceutical form: Solution for administration via spray pump * Route of administration: intranasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)Time frame: From baseline to Week 148

Locations

24 sites in 6 countries. Site status is shown where the registry gives one.

  • Orso Health- Site Number : 8400005

    La Jolla, California

  • Capital Allergy & Respiratory Disease Center- Site Number : 8400003

    Roseville, California

  • Treasure Valley Medical Research- Site Number : 8400002

    Boise, Idaho

  • Essential Medical Research- Site Number : 8400020

    Tulsa, Oklahoma

  • Pharmaceutical Research & Consulting- Site Number : 8400004

    Dallas, Texas

  • The University of Texas Health Science Center- Site Number : 8400017

    Houston, Texas

  • ENT Associates of Texas - McKinney- Site Number : 8400014

    McKinney, Texas

  • Alamo ENT Associates- Site Number : 8400001

    San Antonio, Texas

  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008

    Norfolk, Virginia

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Mendoza, Argentina

  • Investigational Site Number : 0320002

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0560002

    Ghent, Belgium

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 1000001

    Sofia, Bulgaria

  • Investigational Site Number : 6160004

    Poznan, Greater Poland Voivodeship, Poland

  • Investigational Site Number : 6160002

    Krakow, Lesser Poland Voivodeship, Poland

  • Investigational Site Number : 6160007

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Investigational Site Number : 6160001

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160005

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160003

    Katowice, Silesian Voivodeship, Poland

  • Investigational Site Number : 8260003

    Manchester, United Kingdom

  • Investigational Site Number : 8260001

    Newcastle upon Tyne, United Kingdom

  • Investigational Site Number : 8260004

    Gloucester, Gloucestershire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.